Clik here to view.
Heartseed and ITOCHU CHEMICAL FRONTIER Sign Capital Alliance Agreement to...
TOKYO Heartseed Inc. (hereinafter Heartseed), a Tokyo-based biotechnology company developing iPSC-derived cardiomyocytes for the treatment of heart failure (HF), today announced it has entered into...
View ArticleClik here to view.
Notice of Capital and Business Alliance Between Heartseed and MEDIPAL HOLDINGS
TOKYO Tokyo-based Heartseed Inc. (“Heartseed”), a Keio University-originated biotechnology company developing induced pluripotent stem cell (iPSC)-derived cardiac regenerative medicine, and MEDIPAL...
View ArticleClik here to view.
Arima Genomics完成客户验证并上市Arima-HiChIP试剂盒和服务
圣迭戈 (美国商业资讯)–Arima Genomics, Inc.是一家专注于加快基因组结构信息在医学研究、诊断和治疗中应用的生物技术公司，该公司今天宣布，基于其现有Arima-HiC平台打造的HiChIP应用已全面上市。随着此次上市，研究人员现在能通过单次实验获得在感兴趣的蛋白质占据的基因组位点上特别丰富的长距离染色质相互作用，从而能加快发现和发表速度并降低成本。...
View ArticleClik here to view.
Arima Genomics、カスタマーバリデーションを終えてArima-HiChIPのキットおよびサービスを発売
サンディエゴ （ビジネスワイヤ） — ゲノム構造情報の医学研究・診断・治療への採用を促進することに傾注するバイオテクノロジー企業のArima Genomics,...
View ArticleClik here to view.
Notice Regarding Business Alliance Between Sanbio and Ocumension in the...
TOKYO SanBio Co., Ltd. (Keita Mori, Representative Director and President, hereinafter “SanBio”) (TOKYO:4592) hereby announces that SanBio has entered into a business alliance with Ocumension (Hong...
View ArticleClik here to view.
PharmaCyte Biotech Enters into License Agreement for COVID-19 Diagnostic Kits
LAGUNA HILLS, Calif. PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation...
View ArticleClik here to view.
Propanc Biopharma Receives First Allowance for Key Patent Family from...
MELBOURNE, Australia Propanc Biopharma, Inc. (OTC:PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing new cancer treatments for patients suffering from recurring and...
View ArticleClik here to view.
新兴和制药 NMN加强免疫力COVID-19（新冠状病毒）等已开始研究预防和治疗传染病
东京 (美国商业资讯)–新兴和制药株式会社（总部：东京都中央区；代表董事：Tanaka...
View ArticleClik here to view.
Shinkowa Pharmaceutical Launches a Research to Scientifically Substantiate...
TOKYO Shinkowa Pharmaceutical Co., Ltd. (Head Office: Tokyo Chuo-Ward, CEO: Megumi Tanaka) is the largest nutraceutical (health supplemental food which is scientifically proved) producer of...
View ArticleClik here to view.
Legend Biotech and Noile-Immune Biotech Announce Collaborative Research and...
SOMERSET, N.J., USA and TOKYO, Japan Legend Biotech Corporation (“Legend”), a global clinical stage biopharmaceutical company engaged in the discovery and development of novel cell therapies,...
View ArticleClik here to view.
AVITA Medical Limited Proposed Redomiciliation to the United States of...
VALENCIA, Calif. & MELBOURNE, Australia AVITA Medical Limited ACN 058 466 523 (Company) is pleased to announce that it has received confirmation from the Foreign Investment Review Board (FIRB)...
View ArticleClik here to view.
AVITA Medical Limited Proposed Redomiciliation to the United States of...
VALENCIA, Calif. & MELBOURNE, Australia AVITA Medical Limited ACN 058 466 523 (Company) is pleased to confirm that the general meeting to consider a resolution to approve the proposed scheme of...
View ArticleClik here to view.
AVITA Medical Limited Proposed Redomiciliation to the United States of...
VALENCIA, Calif. & MELBOURNE, Australia In accordance with ASX Listing Rule 3.13.3, AVITA Medical Limited ACN 058 466 523 (Company) is pleased to provide a copy of the Chair’s address for the...
View ArticleClik here to view.
AVITA Medical Limited Proposed Redomiciliation to the United States of...
VALENCIA, Calif. & MELBOURNE, Australia AVITA Medical Limited ACN 058 466 523 (Company) is pleased to announce that shareholders today voted in favour of the scheme of arrangement to effect a...
View ArticleClik here to view.
苏爱康宣布Darinaparsin（外周T细胞淋巴瘤）关键2期临床研究结果为阳性
日本东京 (美国商业资讯)–苏爱康制药有限公司（东京证券交易所代码：4597， 总部：日本东京，总裁兼首席执行官：荒井好裕，以下简称“苏爱康”）,一家总部位于亚洲的专业制药公司，今日宣布苏爱康产品-02关键2期临床研究结果为阳性（一种抗癌新药，国际通用名为Darinaparsin）用于在亚洲地区治疗复发或难治性外周T细胞淋巴瘤治疗（以下简称“PTCL”）。 主要终点（抗肿瘤效应）已实现；...
View ArticleClik here to view.
ソレイジア・ファーマ: 開発品SP-02臨床試験結果に関するお知らせ
東京 （ビジネスワイヤ） — 当社は、開発品SP-02（新規抗がん剤、国際一般名：darinaparsin、一般名：ダリナパルシン）の、再発又は難治性の末梢性T細胞リンパ腫（以下、「PTCL」）を対象としたアジア国際共同第II相臨床試験（以下、「本試験」）につき、このたび以下の解析結果を得ましたのでお知らせいたします。 主要評価項目（SP-02抗腫瘍効果）を達成した...
View ArticleClik here to view.
Solasia Announces Positive Results of DARINAPARSIN in Pivotal Phase 2 Study...
TOKYO Solasia Pharma K.K. (TOKYO:4597, Headquarters: Tokyo, President & CEO: Yoshihiro Arai, hereinafter “Solasia”), a specialty pharmaceutical company based in Asia, today announced the...
View ArticleClik here to view.
AVROBIO Announces the Appointment of Kim Raineri as Chief Manufacturing and...
CAMBRIDGE, Mass. AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced the appointment of Kim...
View ArticleClik here to view.
Urethral Stricture Treatment by Hybrid Cell Therapy, Granted Japanese Patent
TOKYO Treating male urethral stricture with the patient’s own buccal mucosal cells, encapsulated in a polymer scaffold as carrier, has been granted a patent in Japan. A longer duration of relief to...
View ArticleClik here to view.
治疗尿道狭窄的混合细胞疗法获得日本专利
东京 (美国商业资讯)–用封装在聚合物支架中的患者自身颊粘膜细胞作为载体治疗男性尿道狭窄，已在日本获得专利。 据报道，以往接受传统治疗后病情复发的患者采用这种称为“Bees-Haus”（颊上皮扩张和支架封装混合法治疗尿道狭窄；https://onlinelibrary.wiley.com/doi/full/10.1111/iju.13852）的方法，可获得更长的缓解持续时间。...
View Article